GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has awarded restricted stock units (RSUs) to 38 new non-executive employees as employment inducement grants. The RSUs cover 77,350 shares of GRAIL common stock and were granted under the company's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over approximately four years, with 25% vesting on May 31, 2026, and the remaining portions vesting annually thereafter, contingent on continued employment with GRAIL or its subsidiaries.

Positive

• Successful recruitment of 38 new non-executive employees indicating company growth
• Implementation of employee retention strategy through equity-based compensation

Negative

• None.

MENLO PARK, Calif., May 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 77,350 shares of GRAIL's common stock to 38 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over an approximately four year period, with 25% of the award vesting May 31, 2026, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302469713.html

SOURCE GRAIL, Inc.

FAQ

How many shares of GRAIL (GRAL) stock were granted as RSUs in May 2025?

GRAIL granted RSUs underlying 77,350 shares of common stock to 38 new non-executive employees.

What is the vesting schedule for GRAIL's May 2025 RSU grants?

The RSUs vest over approximately 4 years, with 25% vesting on May 31, 2026, and the remaining portions vesting annually thereafter.

How many new employees received RSU grants from GRAIL in May 2025?

38 new non-executive employees received RSU grants from GRAIL.

What is the purpose of GRAIL's Inducement Equity Incentive Plan?

The plan is exclusively used to grant equity awards to new employees as an inducement for joining GRAIL, in accordance with Nasdaq Rule 5635(c)(4).